- Conditions
- Rhinitis, Urticaria
- Interventions
- levocetirizine or placebo
- Drug
- Lead sponsor
- Wake Forest University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 61
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Participants, Chronic Spontaneous Urticaria
- Interventions
- AK006-IV, Placebo-IV, AK006-SC, Placebo-SC
- Drug
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 16 more
- Conditions
- Chronic Idiopathic Urticaria
- Interventions
- Omalizumab Injection, Xolair Prefilled Syringe
- Drug
- Lead sponsor
- Kashiv BioSciences, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Brandon, Florida • Brooksville, Florida • Miami Lakes, Florida + 1 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- CDX-0159, Normal Saline
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Sarasota, Florida + 10 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Ligelizumab, Omalizumab, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,078 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 29 more
- Conditions
- Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
- Interventions
- Not listed
- Lead sponsor
- Target PharmaSolutions, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 15,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2050
- U.S. locations
- 54
- States / cities
- Scottsdale, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 48 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- LOU064 Arm 1, LOU064 Arm 2, LOU064 Arm 3, LOU064 Arm 4, LOU064 Arm 5, LOU064 Arm 6, Placebo arm
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 11
- States / cities
- Litchfield Park, Arizona • Little Rock, Arkansas • Mission Viejo, California + 8 more
- Conditions
- Chronic Urticaria
- Interventions
- TEV-45779, XOLAIR® Injection
- Combination Product
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 9
- States / cities
- Bakersfield, California • Clearwater, Florida • Coral Gables, Florida + 6 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Nucala
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Chronic Idiopathic Urticaria
- Interventions
- Xolair
- Biological
- Lead sponsor
- Asthma Inc Clinical Research Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 9
- States / cities
- Coral Gables, Florida • Boise, Idaho • St Louis, Missouri + 6 more
- Conditions
- Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis
- Interventions
- KPL-716, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 14
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 11 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- QGE031, Omalizumab, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 22 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Ligelizumab
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 14 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- barzolvolimab, Matching Placebo
- Biological · Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 10 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Dupilumab SAR231893, Placebo, non sedating H1-antihistamine
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years to 80 Years
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Sarasota, Florida • Sweetwater, Florida + 13 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Lirentelimab (AK002), Placebo
- Drug · Other
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 44 more
- Conditions
- Chronic Idiopathic Urticaria
- Interventions
- Placebo, Omalizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 36
- States / cities
- La Jolla, California • Los Angeles, California • Redwood City, California + 31 more
- Conditions
- Urticaria
- Interventions
- GDC-0853, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 10 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- barzolvolimab, Matching placebo
- Biological
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 976 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 63
- States / cities
- Cullman, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 47 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg, Placebo - 100 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 12 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Tezepelumab Dose 1, Tezepelumab Dose 2, Omalizumab, Placebo
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Laguna Niguel, California + 21 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- LOU064 25 mg (b.i.d), Placebo, LOU064 25 mg (b.i.d) as a tablet.
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • North Little Rock, Arkansas • Bakersfield, California + 23 more
- Conditions
- Chronic Urticaria
- Interventions
- Omalizumab
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Denver, Colorado